Immatics’ Series D Adds $46M for Phase III Renal Cancer Trial

By Nuala MoranStaff Writer

Tuesday, October 15, 2013

LONDON – Immatics Biotechnologies GmbH closed a €34 million (US$46.1 million) Series D financing, enabling it to complete Phase III development of its lead cancer vaccine IMA901 in renal cancer and complete all preparations for filing with the FDA and the European Medicines Agency.